Myeloproliferative neoplasm test kit HEMARNA™

for lymphomafor acute myeloid leukemiafor acute lymphoblastic leukemia

DNA sequencing alone or in combination with RNA sequencing can provide valuable insight to the key genetic features involved in hematologic malignancies, especially alterations that may be less common or those that provide an opportunity for targeted therapy. We offer pan-cancer panels designed to help identify the most suitable treatment for patients with hematologic malignancies. Targets 232 fusion genes in hematolymphoid tumors Hematolymphoid tumors are a group of highly heterogeneous diseases. So far, more than 100 fusion genes have been introduced in the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. Fusion gene testing is crucial in diagnosis, treatment decision making, MRD monitoring and prognosis. WHO IS IT FOR Early fusion screening for patients with hematolymphoid tumors (including acute lymphoblastic lymphoma, acute myeloid leukaemia, myeloproliferative neoplasms, and lymphomas) Patients with hematolymphoid tumors but are ‘pan-negative’ or have non-classical fusions and require further fusion testing Patients with specific fusion mutations undergoing dynamic monitoring after treatment or relapse SAMPLE TYPES Tumor tissue (FFPE block/slides, or frozen tissue) Fine needle biopsy